Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.86 |
| ▸ | CHAT | P28329 | 2/20 | 0.82 |
| ▸ | EP300 | Q09472 | 2/20 | 0.81 |
| ▸ | AURKA | O14965 | 2/20 | 0.81 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.81 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29457604 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT2B | |
| SCHEMBL28671996 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT2B | |
| SCHEMBL17997995 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT2B | |
| SCHEMBL12934617 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT2B | |
| SCHEMBL4286414 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT2B | |
| SCHEMBL30582704 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT2B | |
| SCHEMBL187858 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT2B | |
| SCHEMBL188315 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT2B | |
| SCHEMBL25429 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT2B | |
| SCHEMBL30074506 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| EP-4713320-A2 | BCAT2 INHIBITORS | Agios Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2025229221-A1 | METHOD OF DETECTION OF METHYLMALONIC ACID (MMA) AND/OR A RELATED MMA COMPOUND | William Oak Diagnostics Limited (GB) | 2025-11-06 | — | — | WO | disclosed |
| US-12374439-B2 | Methods and systems for generating a vibrant compatibility plan using artificial intelligence | KPN INNOVATIONS LLC (US) | 2025-07-29 | — | — | US | disclosed |
| CN-119855613-A | Fatty acid-D-amino acid peptide conjugates as anaplerotic compounds for the treatment of hyperuricemia, methylmalonic urine disorder and energy metabolism disorders | 匹兹堡大学高等教育联邦体系 | 2025-04-18 | — | — | CN | disclosed |
| EP-4507740-A1 | LENTIVIRAL VECTOR | Genespire S.r.l. (IT) | 2025-02-19 | — | — | EP | disclosed |
| US-20250049952-A1 | IMPROVED GENE THERAPY CONSTRUCTS FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHA | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2024238820-A2 | BCAT2 INHIBITORS | AGIOS PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | HEMOSHEAR THERAPEUTICS INC (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2024182718-A2 | COMPOSITIONS AND METHODS RELATED TO TRANSCOBALAMIN RECEPTOR AUTOANTIBODIES | CZ BIOHUB SF, LLC (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20230230673-A1 | METHODS AND SYSTEMS FOR GENERATING A VIBRANT COMPATIBILITY PLAN USING ARTIFICIAL INTELLIGENCE | KPN INNOVATIONS, LLC. (US) | 2023-07-20 | — | — | US | disclosed |
| WO-2023130003-A2 | IMPROVED GENE THERAPY CONSTRUCTS FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHA | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2022216848-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | Hemoshear Therapeutics, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220325266-A1 | SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE BETA | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-10-13 | — | — | US | disclosed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | disclosed |
| US-20220251536-A1 | SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHA | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3997080-A1 | BCAT MODULATION | Icagen, LLC (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3990029-A1 | SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHA | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022031859-A2 | METHYLMALONIC ACID AND METABOLISM THEREOF IS A CANCER BIOMARKER AND TARGET | CORNELL UNIVERSITY (US) | 2022-02-10 | — | — | WO | disclosed |
| CN-108140848-B | Automated biological nanocatalyst production | 齐姆特罗尼克斯公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | MMAB, OTC, ME2 | NAA50 3556/4885CHAT 1146/4885EP300 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.